AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round

Geneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million).

View PDF